WCA
MCRB icon

Windsor Creek Advisors’s Seres Therapeutics MCRB Stock Holding History

Windsor Creek Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-500
Closed -$35 – 194
2019
Q4 		$35 Buy
+500
New +$37.1K 0.01% 132

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Windsor Creek Advisors's MCRB Position: Q1 2020 in Review

Windsor Creek Advisors sold out of Seres Therapeutics (MCRB) in Q1 2020, closing a stake of 500 shares — an estimated $35 sold.

Windsor Creek Advisors first reported a position in MCRB in Q4 2019 and held it in 1 quarter. The position peaked at $35 in Q4 2019. 77 funds tracked by Wall St. Rank hold MCRB as of Q1 2020.

  • Windsor Creek Advisors reported no remaining Seres Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Windsor Creek Advisors sold 500 Seres Therapeutics shares in Q1 2020, an estimated $35.
  • Windsor Creek Advisors first reported a position in Seres Therapeutics in Q4 2019 and held it in 1 quarter.
  • Windsor Creek Advisors's Seres Therapeutics position peaked at $35 in Q4 2019.
  • 77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2020.

Based on Windsor Creek Advisors's 13F filing for Q1 2020, filed 12 May 2020.